Sort by
Refine Your Search
-
the peculiar optical properties of nanostructures and state of the art instrumentation for optical imaging. The methodology will be explored within the context of drug-target interactions of importance to early
-
interaction with a large and diverse group of excellent researchers. The facilities include laboratories dedicated to biomedical research, including cell culture facilities and wet labs, as well as access
-
The Project The project focuses on understanding and improving the stability of lipid nanoparticles (LNPs) for use in vaccines. By investigating molecular interactions and structural properties
-
. State-of-the art and advanced methodologies are applied in a professional research environment characterized by its well-established international profile. The institute has 30 research groups with a
-
(e.g., model compression/simplification and hardware-aware optimization). We are also interested in how resource-efficiency interacts with broader sustainability aspects of machine learning such as
-
Department of Molecular Sciences conducts research, teaching and has state-of the art equipment in filtration and advanced infrastructure for microscopy, molecular characterization, X-ray and NMR. We offer
-
inference and deployment costs (e.g., model compression/simplification and hardware-aware optimization). We are also interested in how resource-efficiency interacts with broader sustainability aspects
-
to learn about isotope tracing techniques and explore how soil microbes respond to environmental stress. You will join a creative, supportive research environment with access to state-of-the-art isotopic and
-
-of-the-art drug design technologies to develop novel peptide-based immunomodulatory therapies. Within this environment, Dr. Ganna Petruk is establishing an independent research niche focusing on systemic
-
at the Department of Clinical Sciences Lund integrates discoveries on the body’s own peptide-based defence mechanisms with state-of-the-art drug design technologies to develop novel peptide-based immunomodulatory